Clinical implications for Vascular Endothelial Growth Factor in the lung: friend or foe?

Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis which has multiple effects in lung development and physiology. VEGF is expressed in several parts of the lung and the pleura while it has been shown that changes in its expression play a significant role in the pathophysiology of some of the most common respiratory disorders, such as acute lung injury, asthma, chronic obstructive pulmonary disease, obstructive sleep apnea, idiopathic pulmonary fibrosis, pulmonary hypertension, pleural disease, and lung cancer. However, the exact role of VEGF in the lung is not clear yet, as there is contradictory evidence that suggests either a protective or a harmful role. VEGF seems to interfere in a different manner, depending on its amount, the location, and the underlying pathologic process in lung tissue. The lack of VEGF in some disease entities may provide implications for its substitution, whereas its overexpression in other lung disorders has led to interventions for the attenuation of its action. Many efforts have been made in order to regulate the expression of VEGF and anti-VEGF antibodies are already in use for the management of lung cancer. Further research is still needed for the complete understanding of the exact role of VEGF in health and disease, in order to take advantage of its benefits and avoid its adverse effects. The scope of the present review is to summarize from a clinical point of view the changes in VEGF expression in several disorders of the respiratory system and focus on its diagnostic and therapeutic implications.


Background
Over the past few years extensive research has been done on the role of vascular endothelial growth factor (VEGF) in several physiologic and pathologic conditions in the lung. VEGF is a pluripotent growth factor that is critical for lung development and has multiple physiological roles in the lung, including the regulation of vascular permeability and the stimulation of angiogenesis. Increasing evidence in the current medical literature suggests that VEGF additionally plays significant role in the development of several lung disorders, including lung cancer, chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH) and acute lung injury (ALI) [1]. However, in many of these disorders the role of VEGF is not clear, as contradictory reports suggest both protective and deleterious mechanisms of action. The aim of the present review is to summarize the changes on the expression of VEGF in the lung and the pleura in several pathologic conditions of the respiratory system, and to focus on the diagnostic and therapeutic implications of VEGF in lung diseases.

What is VEGF?
VEGF is one of the most potent mediators of vascular regulation in angiogenesis and vascular permeability to water and proteins [2]. VEGF is believed to increase vascular permeability 50,000 times more than does histamine [3]. It has been also reported that VEGF induces fenestration in endothelial cells both in vivo and in vitro [4]. Over the past few years several members of the VEGF gene family have been identified, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor (PLGF) [5]. The most studied molecule of the VEGF family is VEGF-A, also referred as VEGF.
The biological activity of VEGF is dependent on its reaction with specific receptors. Three different receptors have been identified that belong to the tyrosine-kinase receptor family: VEGFR-1/Flt-1, VEGFR-2/Flk-1 (KDR), and VEGFR-3 (Flt-4). Both VEGFR-1 and VEGFR-2 have extracellular immunoglobulin-like domains as well as a single tyrosine kinase transmembrane domain and are expressed in a variety of cells [7]. VEGFR-3 is a member of the same family but it is not a receptor for VEGF as it binds only VEGF-C and VEGF-D [5]. VEGFR-3 is predominantly expressed in the endothelium of lymphatic vessels. Neuropilin-1, a receptor for semaphorins in the nervous system, is also a receptor for the heparin-binding isoforms of VEGF and PIGF. However, there is no evidence that neuropilin signals after VEGF binding. It has been proposed that neurophilin-1 presents VEGF 165 to Flk-1/KDR in a manner that enhances the effectiveness of Flk-1/KDR signal transduction [6].

Transcriptional and post transcriptional regulation of VEGF
VEGF gene expression is known to be regulated by several factors, including hypoxia, growth factors, cytokines and other extracellular molecules [8]. Hypoxia plays a key role in VEGF gene expression both in vivo and in vitro, while VEGF mRNA expression is induced after exposure to low oxygen tension [6]. Hypoxia-induced transcription of VEGF mRNA is apparently mediated by the binding of hypoxia-inducible factor 1 (HIF-1) to an HIF-1 binding site located in the VEGF promoter [8]. In addition to the induction of VEGF gene transcription, hypoxia also promotes the stabilization of VEGF mRNA, which is labile under conditions of normal oxygen tension, by proteins that bind to sequences located in the 3' untranslated region of the VEGF mRNA [9,10]. There is also evidence that the hypoxia-mediated elevation in VEGF transcription is also mediated by sites that are found in the 5' untranslated region of the VEGF mRNA [8]. Except the HIF-1 transcription binding side, VEGF promoter region has several potential transcription factor binding sites such as AP-1, AP-2, Egr-1, Sp-1 and many others which are also involved in VEGF transcription regulation [11].
The human VEGF gene contains two hypoxia-sensitive enhancer elements and several consensus binding sites for growth factor regulated transcription factors [12]. The presence of these regulatory sequences suggest the synergistic effect of boyh hypoxia and growth factors at the level of transcription [12]. Growth factors that can stimulate VEGF production include epidermal growth factor (EGF), transforming growth factor β (TGF-β), keratinocyte growth factor (KGF) and insulin like growth factor (IGF) [5,8]. These observations suggest that the paracrine or autocrine release of such factors cooperates with local hypoxia in regulating VEGF release in the microenvironment [5].
Other studies have shown that the product of the von Hippel-Lindau (VHL) tumor suppressor gene plays an important role in HIF-1 dependent hypoxic responses and provides negative regulation of many hypoxia inducible genes, including VEGF gene [5]. VHL inhibition of VEGF expression is mediated by transcriptional and post transcriptional mechanisms. At the transcriptional level, VHL forms a complex with the Sp1 transcription factor and inhibits Sp1-mediated VEGF expression as a result of the binding of Sp1 to a specific region in the VEGF promoter [8]. At the post transcriptional level, VHL inhibits the activity of several protein kinases which stabilize VEGF mRNA. It is known that mutations in the VHL gene are associated with VEGF overexpression and increased angiogenesis [8].

Interdependence of VEGF with other angiogenic factors
Vascular development is the result of collaboration between three different families of growth factors: VEGFs, angiopoietins and ephrins [13]. Incorporation of those three different kinds of growth factors in a model of vascular formation has showed that VEGF initiates the formation of vascular vessels by vasculogenesis or angiogenic sprouting both during development and in the adult. Angiopoietin-1 and ephrin B 2 are required for further remodeling and maturation of this initially immature vasculature [14]. It has been reported that VEGF administration in animal models promotes by itself only leaky, immature and unstable vessels. Administration of angiopoietin-1 stabilizes and protects the adult vasculature making it resistant to the damage and leak induced by VEGF or inflammation [14]. Existing data suggest that VEGF and angiopoietins act in a very complementary and coordinated fashion [13]. Finally, the ephrins, are acting in later stages of vascular development though they may also contribute somewhat to the formation of vessel primordia [13]. It is important that all of these factors must collaborate in perfect harmony to form functional vessels [14].

The role of VEGF in lung development
The formation of lung's vasculature includes three processes: angiogenesis, which gives rise to the central vessels via the sprouting of new vessels from preexisting ones; vasculogenesis, which provides the peripheral vessels via the formation of capillaries from blood lakes; and fusion between the central and peripheral systems to create the pulmonary circulation. A likely candidate as a regulator for the formation of the lung's vasculature in all three phases is VEGF [15]. High levels of VEGF protein and mRNA have been detected in the developing lung, suggesting that VEGF plays a central role in the formation of lung vasculature and also in the epithelial-endothelial interactions that are critical for normal lung development [16].
The expression of VEGF mRNA and protein is localized to the distal airway epithelial cells in the midtrimester human fetal lung and their levels increase with time; [16] in contrast, VEGF levels are decreased in human infants with bronchopulmonary dysplasia (BPD). Furthermore, the inhibition of the VEGF receptors in the immature lung reduces eNOS expression and NO bioactivity and later leads to the development of the structural and functional features of BPD [17]. Finally, VEGF stimulates surfactant production by alveolar type II cells, which results in lung maturation and protects from the development of respiratory distress syndrome of the newborn [18].

VEGF protein and VEGF receptors in the lung and the pleura
Although VEGF has been characterized as a mitogen for vascular endothelial cells, recent studies identified the presence of VEGF and its receptors in several cell types in many organs. It has been reported that lung presents the highest level of VEGF gene expression among normal tissues [19]. VEGF and its receptors (VEGFR-1, VEGFR-2 and NRP1) have been detected in alveolar type II cells, airway epithelial cells, mesenchymal cells, airway and vascular smooth muscle cells, macrophages and neutrophils [7,20]. In healthy human subjects, VEGF protein is composed in the lung and VEGF protein levels in alveoli are 500 times higher than in plasma [21]. It has been proposed that the high levels of VEGF protein on the respiratory epithelial surface may function as a physiological reservoir [21]. Potential cellular sources of VEGF include alveolar and airway epithelial cells [22], as well as airway smooth muscle cells [21]. Normal lung alveolar macrophages produce very small amounts of VEGF. Additionally, although neutrophils carry intracellular pools of VEGF, their number in normal lung is very low [7]. Therefore, neither of those two types of cells is likely to affect VEGF levels in alveoli in health. In normal lung, VEGF may slowly diffuse across the alveolar epithelium to the adjacent vascular endothelium and act in a paracrine fashion [7]. However, in disease states, the expression of VEGF or its receptors is affected, and that is often related to the pathophysiology and the particular characteristics of each disease. In addition, human mesothelial cells are known to be a source of elevated concentrations of VEGF in the pleural fluid [23], and these cells have also been shown to be positive for VEGFR-1 [24].

Where can VEGF be measured?
VEGF has been measured in several kinds of biological fluids and cells of the lung parenchyma. The most common origins used for its measurements are blood (serum or plasma), bronchoalveolar lavage (BAL) fluid, sputum, bronchial epithelial cells, alveolar type II cells, alveolar macrophages, neutrophils, endothelial cells of the alveolar capillaries, and airway or vascular smooth muscle cells.
It is important to point out that serum VEGF levels are higher compared to those measured in plasma. The reason for that difference, is that serum VEGF reflects ex vivo platelet and leukocyte release during blood clotting, thus resulting in an increase of VEGF concentrations by 2-to 7fold [25]. In BAL fluid, VEGF levels actually correspond to VEGF levels of the epithelial lining fluid. To estimate VEGF concentrations in epithelial lining fluid, investigators have taken into account the generally accepted estimate that pooled BAL fluid is diluted 100 times compared with alveolar fluid [22]. In healthy human subjects, epi-thelial lining fluid VEGF protein levels are 500 times higher than plasma levels [21].

VEGF in diseases of the lung and the pleura
The consequences of the administration or inhibition of VEGF have been widely studied in animal models (Table  1). In humans, elevated or reduced VEGF levels have been found in various respiratory disorders ( Table 2) and have been associated with various clinical manifestations of those disease entities (Table 3). A detailed description of the role of VEGF in diseases of the lung and the pleura follows.

Acute lung injury and acute respiratory distress syndrome
The acute respiratory distress syndrome (ARDS) is the most extreme manifestation of acute lung injury (ALI) [26]. Pulmonary injury in ARDS results in the disruption of the alveolar-capillary membrane which leads to a severe dysfunction of gas exchange and chest radiographic abnormalities, following a predisposing injury and in the absence of heart failure [7]. The hallmarks of ALI are increased capillary permeability, interstitial and alveolar edema, influx of circulating inflammatory cells, and formation of hyaline membranes [7]. It is commonly believed that inflammatory mediators create an acute inflammatory response in the microvessels of the lung and that locally released inflammatory cell products damage the endothelial cells resulting in increased permeability [27]. A wide range of vasoactive agents is released and modulates vascular tone at a local level. The result is a loss of functional and structural vascular integrity. VEGF has been shown to play a key role in this process.
The potential role of VEGF in ARDS has been studied in both sides of the alveolar capillary interface [27,28]. It has been shown that plasma VEGF levels in subjects with ARDS were elevated compared to controls [27]. Additionally, the time-course of VEGF was associated to the patients' outcome, with VEGF plasma levels being higher in non-survivors compared to survivors [27]. Interestingly, increases in plasma VEGF over 100% baseline val-ues were associated with 100% mortality [27]. The same authors consequently reported that VEGF levels in the epithelial lining fluid of patients with ARDS were significantly lower than in controls [28]. In contrast to plasma measurements, increasing epithelial lining fluid VEGF levels were associated with recovery [28]. The authors suggested that lung might represent a physiological reservoir of VEGF with potentially devastating effects if the epithelial barrier is breached [28].
Additionally, the intratracheal administration of VEGF has been shown to provoke a dose-dependent increase in extravascular lung water, while lung histology showed widespread intra-alveolar edema, and increased pulmonary capillary permeability [19]. According to the above, one could conclude that in the case of hydrostatic pulmonary edema, in which the alveolar capillary membrane is normal, VEGF levels in the pulmonary edema fluid should be higher than in the case of ALI/ARDS [29]. However, VEGF levels did not differ between patients with hydrostatic pulmonary edema and ALI/ARDS neither in the pulmonary edema fluid nor in plasma [29]. Those data suggest that a possible explanation for the decreased levels of alveolar VEGF in both ALI/ARDS and hydrostatic pulmonary edema may be the dilution caused from the alveolar flooding rather than the degree of lung injury [29].
In the early stage of lung injury different insults and proinflamatory cytokines stimulate the production and release of VEGF from type II cells, alveolar macrophages and neutrophils. Therefore, the epithelial-endothelial barrier is exposed to high concentrations of VEGF, which increases vascular permeability and leads to interstitial edema [7]. During the development of lung injury, damage of alveolar epithelial cells reduces the production of VEGF and leads to the low concentration detected in the BAL fluid of these patients. The release of VEGF from other organs and circulating leucocytes may additionally contribute to the increased serum concentration of VEGF in patients with ALI/ARDS [7]. Finally, during the recovery of lung injury,

Intervention
Result Reference

Provocation of intratracheal VEGF overexpression in mice
Dose-dependent increase in extravascular lung water intra-alveolar edema, and increased pulmonary capillary permeability. [19] Administration of a VEGFR inhibitor in mice Decrease in bronchial hyperresponsiveness and migration of inflammatory cells through the endothelial basement membrane and reduction of VEGFinduced plasma leakage. [42] Intraperitoneal administration of a VEGF receptor blocker in rats Induction of alveolar septal cell apoptosis and enlargement of air spaces (emphysema). [46] VEGF gene transfer in immature rabbits Reduction of bleomycin-induced pulmonary hypertension.
[78] Blockade of VEGF activity in malignant pleural effusion model in mice Decrease of vascular permeability and reduction of pleural fluid. [3,113] VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor.
alveolar cells are being repaired and increased local production of VEGF may play a role in the repair and angiogenesis by acting on VEGFR-2 [7]. On the other hand it has been shown that VEGF production stimulated by IL-13 in transgenic mice leads to a protection against hyperoxic acute lung injury [30]. It has also been suggested that VEGF is critical for pulmonary angiogenesis, as it stimulates endothelial cell growth. It also seems to play a role in lung epithelial cell proliferation. According to that, regulation of VEGF synthesis in the lung may affect lung injury repair [22].
These observations indicate that the expression and function of VEGF in ALI/ARDS vary. The results of its biological activity depend on the pathophysiological conditions, the timing and the degree of epithelial and endothelial [45] Obstructive sleep apnea Correlation of circulating VEGF levels with the severity of OSA (as expressed by the apneahypopnea index) and with the degree of nocturnal desaturations.
[25, 53] [55] Idiopathic Pulmonary Fibrosis Correlation of plasma VEGF levels of with the extent of parenchymal involvement in HRCT.
Correlation of VEGF concentrations in BAL fluid with DL CO . [59] [60-62] Tuberculosis Higher serum VEGF levels in TB patients without cavitary lesions compared to those with typical chest cavities. [70] Lung Cancer Correlation of the expression of VEGF with tumor size.
[98] Patients with higher serum VEGF levels had lower survival compared to patients with lower VEGF levels.
[96, 100-103] VEGF: vascular endothelial growth factor; ALI/ARDS: acute lung injury/acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; BAL: bronchoalveolar lavage; TB: tuberculosis; OSA: obstructive sleep apnea; HRCT: high resolution computed tomography. . Additionally, the increased VEGF levels in asthmatic patients are negatively correlated with the degree of airway obstruction, and positively correlated with the degree of eosinophilic inflammation and an index indicative of vascular permeability [4,36]. This VEGF-related increased vascular permeability in the asthmatic airways has also been proposed as a mechanism that may be in part responsible for the exercise-induced bronchoconstriction in asthmatics [33]. In addition to its role in vascular permeability in the asthmatic mucosa, VEGF has been related to increased basement membrane thickness in biopsies from asthmatic patients, suggesting a possible role of VEGF in airway remodelling [37].
Treatment of asthmatic subjects with inhaled corticosteroids resulted in the decrease of VEGF levels in induced sputum; however, asthmatic patients after treatment had still higher VEGF levels in induced sputum than controls [4,32]. Inhibition of VEGF expression by corticosteroids has additionally been shown in vitro in airway smooth muscle and epithelial cell cultures [38,39]. Cysteinyl leukotriene receptor antagonists reduce VEGF expression in animal models of allergic asthma [40]. A decrease in induced sputum VEGF levels was also observed after treatment of steroid-naive asthmatics with pranlucast, a selective leukotriene receptor antagonist. However, the addition of pranlucast to inhaled corticosteroids added little efficacy to the reduction of airway VEGF levels [41].
In animal models it has also been shown that treatment with a VEGFR inhibitor resulted in reduction of VEGFinduced plasma leakage, decreased bronchial hyperresponsiveness and migration of inflammatory cells through the endothelial basement membrane [42].

Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible, usually progressive, and associated with an abnormal inflammatory response of the lungs in response to noxious particles and gases [43]. However COPD does not seem to be a single entity. Its two major subtypes are chronic bronchitis and emphysema and lead in the two clearly distinguishable phenotypes of the "blue bloater" and the "pink puffer" [44].

Idiopathic Pulmonary Fibrosis (IPF)
The pathogenesis of IPF is characterized by an initial acute inflammatory reaction which may lead to a chronic fibroproliferative process. The pulmonary architecture is profoundly remodelled, with the extracellular matrix and a variety of cell types involved [58]. Lung biopsies in IPF have the histologic appearance of usual interstitial pneumonia, which is characterized by a heterogeneous and non-uniform fibrosing process with alternating zones of fibrosis, honeycomb change and intervening patches of normal lung.  [73].
Plexiform lesions are unique vascular structures that occur in the lungs of patients with primary or secondary PH [74]. VEGF and its receptors flt-1 and flk-1 are expressed in the plexiform lesions and may play a role in the pathogenesis of PH by stimulating dysregulated angiogenesis [71]. In addition, it has been reported that VEGF increases the expression of tissue factor and is likely to play some role in inflammatory responses [72]. Whereas lack of VEGF impaired signaling via the tyrosine kinase receptors causes endothelial cells to die, experimental overexpression of VEGF produces structures that resemble plexiform lesions [72]. Additionally, in animal models with increased pulmonary blood flow and PH the expression of VEGF and its receptors was higher than controls, and that has been suggested to take part in the development of the vascular remodelling seen in PH [75].
In contrast, it has been reported that inhibition of flk-1 in animal models caused pulmonary hypertension characterized by thickening of the medial layer of pulmonary arteries in normoxic conditions. Additionally, in hypoxic conditions, the inhibition of flk-1 lead to more marked pulmonary hypertension developing through an increase in endothelial cell proliferation in the pulmonary artery [76]. These data suggest that VEGF, acting through flk-1, has a protective role and inhibits endothelial cell death [76]. The protective role of VEGF in the development of pulmonary hypertension can also be supported by the fact that VEGF stimulates NO release from vascular endothelium and increases local eNOS expression [77]. Furthermore, it has been shown that gene transfer of VEGF in animal models can reduce bleomycin-induced PH [78].
Finally, it is worthy to mention that platelet VEGF content as well as serum VEGF levels were markedly elevated in patients with primary and secondary PH compared to normal controls, potentially leading to an increase of VEGF at sites of lung injury [79]. Interestingly, platelet VEGF content was further increased by continuous prostacyclin infusion, indicating that prostacyclin increases circulating VEGF levels [79]. The important issue raised from those studies is whether increased platelet VEGF content and potentially increased VEGF released at sites of vascular injury, notably in the pulmonary vasculature, have protective or deleterious effects. The exact role of VEGF in the pathogenesis of human PH and the vascular remodelling inherent in this condition remains unknown [79].

Pleural effusion
Pleural effusion is a common problem in everyday clinical practice and VEGF has been reported to play an important role in the development of certain types of effusion [24].
Effusions associated with malignancies seem to have higher levels of VEGF than benign effusions [24, 81,82,84,85]. Additionally, hemorrhagic malignant effusions presented higher VEGF levels than non-hemorrhagic ones [86,87]. However there are no significant differences in pleural VEGF levels in patients with different histologic types of cancer [82,84], or different clinical stages of lung cancer [82]. VEGF levels in malignant effusions were found to be 10-fold higher than in corresponding serum samples, indicating local release of VEGF within the pleural cavity [88]. It has been suggested that increased VEGF levels in the malignant pleural effusions increases vascular permeability and contributes to fluid accumulation [3,83].
Empyema fluid contains high levels of VEGF, which are significantly higher compared to VEGF levels in uncomplicated parapneumonic effusions [24,89]. It has been suggested that bacterial pathogens induce VEGF release from mesothelial cells and alter mesothelial permeability leading to protein exudation [89]. VEGF levels are higher in tuberculous pleural effusions compared to transudates [90]. In the same study, serum VEGF levels were higher compared to the pleural fluid in patients with tuberculous effusions, implicating that VEGF may promote increased vascular permeability that leads to effusion formation [90]. Finally, Isolated cases of pleural effusions due to pulmonary emboli had very high VEGF levels, probably related to tissue ischemia [81].
Despite the statistically significant differences in pleural fluid VEGF levels between malignant and non malignant effusions, substantial overlap exists, suggesting that VEGF levels are unlikely to be useful diagnostically as a single marker [81]. However it has been proposed that VEGF levels above 1000 pg/ml in pleural fluid are suggestive of either empyema or malignancy [24].

Lung cancer
VEGF is a potent angiogenic mediator and angiogenesis has important effects on tumor growth and metastasis. Expression of VEGF may therefore be an indicator for the angiogenic potential and biological aggressiveness of a

Miscellaneous
Measurement of VEGF levels has been a subject of research in several lung diseases. In cystic fibrosis elevated serum VEGF levels were found and were further increased during pulmonary exacerbations [105]. VEGF levels in BAL fluid of patients with acute eosinophilic pneumonia are higher than normal controls and rapidly decrease to the control level with clinical improvement; these findings suggest an important role for VEGF in the pathogenesis of pulmonary edema in eosinophilic pneumonia [106]. VEGF levels are also increased in BAL fluid, serum and tissue of patients with hypersensitivity pneumonitis, suggesting that abnormal expression of VEGF may contribute to impair the lung repair in this disease [107].

Therapeutic implications and perspectives
The fact that VEGF levels correlated with cancer staging and prognosis, has supported the idea of using anti-VEGF strategies, such as anti VEGF antibodies (e.g. bevacizumab) or inhibitors of the VEGF receptors in combination with chemotherapy or alone to improve survival of patients with metastatic NSCLC [103,108]. Generally tumors cannot grow beyond 2 mm in diameter without developing vascular supply. Neovascularization permits further growth of the primary tumor, but it also provides a pathway for migrating tumor cells to gain access to the systemic circulation and to establish distant metastases [109]. As VEGF and its receptors play an important role in tumor growth and metastasis, the use of anti-VEGF agents and VEGF-R inhibitors for the treatment of lung cancer is currently in development, and bevacizumab is the first anti-VEGF factor that has already been used in patients with lung cancer [110].
RhuMab VEGF, is a recombinant humanized monoclonal antibody to VEGF that has been shown to inhibit the growth of a variety of human cancer cell lines [111]. This agent may act synergistically with chemotherapy and is currently being tested in lung cancer. The VEGF system can also be targeted through inhibition of VEGFR, by the use of monoclonal antibodies or specific tyrosine kinase inhibitors [111]. Currently studied inhibitors of VEGFR include SU5416 (a VEGFR-2 inhibitor) and SU6668 (a VEGFR-1 inhibitor). Although SU5416 suppresses tumor growth in animal models [112], neither of these agents will be developed further in view of their adverse toxicity profile [111]. Other inhibitors such as ZD6474, and CP-547,632 are still under research [111].
Blockade of VEGF activity in malignant pleural effusions has been proposed as an intervention to decrease permeability and reduce pleural fluid [3,113]. On the other hand, in animal models where pleurodesis was induced with TGF-β 2 , treatment with anti-VEGF antibody before TGF-β 2 injection resulted in decrease of the amount of angiogenesis and inhibition of pleurodesis [114]. As agents that act as anti-VEGF agents are now being used in the treatment of several different tumors, one should probably not attempt to perform pleurodesis when the patient has already been receiving an agent that inhibits angiogenesis [114].
The use of VEGFR-2 inhibitors has been proposed as additional therapy for patients with progressive pulmonary fibrosis [59]. However, other investigators have reported that antagonizing VEGF would not be a successful potential treatment for patients with pulmonary fibrosis as they suggest that this would hasten epithelial cell apoptosis and promote alveolar septal cell loss resulting to honeycombing and functional deterioration [115].

Conclusion
Conclusively, the answer to the question "friend or foe" for VEGF in the lung is not an obvious one. VEGF may have a protective role in specific areas of the lung and a deleterious role in other areas, being part of a procedure which leads to damage. The lack of VEGF in some disease entities may provide an indication for its substitution, whereas its overexpression in other pathological conditions has led to efforts for blockage of its actions. The only possible answer that could be given is that VEGF in the lung could be a good friend as long as it is present in the right amount, in the right place and in the right time. Further research is still needed for the complete understanding of the exact role of VEGF in health and disease, in order to take advantage of its benefits and avoid its adverse effects.